spacer
home > ebr > autumn 2017 > eu impact
PUBLICATIONS
European Biopharmaceutical Review

EU Impact

25 May 2018 is an important date for pharmaceutical companies, CROs, software vendors and others supporting drug development, as this is when the new EU General Data Protection Regulation (GDPR) – what the EU calls “the most important change in data privacy regulation in 20 years” – comes into effect (1).

The new rules replace the 1995 Data Protection Directive 95/46/EC and are meant to harmonise data privacy laws across Europe, as well as “to protect and empower all EU citizens’ data privacy”. The GDPR will have a significant impact on how patient data are handled as it changes the way organisations approach information security.

When GDPR comes into effect, national governments will not be required to pass enabling legislation. The regulation will be applicable immediately, and serious violations may result in fines of €20 million or 4% of the organisation's worldwide revenues.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jon Weisberg, Industry Advisor for EBR, heads public relations and communications for SAFE-BioPharma Association. He provides comprehensive editorial and consulting services to life sciences organisations.
spacer
Jon Weisberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma Celebrates 15 Years of Growth and Success

Vilnius, Lithuania, July 16, 2019 ─ Northway Biotechpharma, a leading biopharmaceutical contract development and manufacturing organization (CDMO), celebrates its 15th anniversary today. As a midsized CDMO, Northway Biotechpharma is able to provide flexibility and responsiveness backed by a strong foundation in science and technology. The company focuses on understanding its customers and meeting their specific needs without binding them to one single approach. It is able to react rapidly to unexpected project changes, adjusting timelines, capacities and other activities to meet its customers’ evolving needs. On average, Northway Biotechpharma has 25–30 development projects underway each year, ranging from gene cloning to final drug product manufacturing.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement